Royal Bank of Canada Has $30.67 Million Holdings in Haleon PLC Sponsored ADR $HLN

Posted by Stanley Muller on Aug 4th, 2026

Royal Bank of Canada lifted its stake in shares of Haleon PLC Sponsored ADR (NYSE:HLN – Free Report) by 8.5% in the 1st quarter, Holdings Channel reports. The fund owned 3,063,916 shares of the company’s stock after acquiring an additional 238,841 shares during the quarter. Royal Bank of Canada’s holdings in Haleon were worth $30,671,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also made changes to their positions in HLN. Norges Bank bought a new stake in Haleon in the 4th quarter valued at $163,529,000. Natixis Advisors LLC increased its holdings in Haleon by 429.8% during the 4th quarter. Natixis Advisors LLC now owns 10,003,941 shares of the company’s stock worth $101,140,000 after purchasing an additional 8,115,633 shares in the last quarter. Arrowstreet Capital Limited Partnership raised its stake in shares of Haleon by 4,315.4% in the 4th quarter. Arrowstreet Capital Limited Partnership now owns 8,027,189 shares of the company’s stock valued at $81,155,000 after purchasing an additional 7,845,391 shares during the period. Bank of Montreal Can raised its stake in shares of Haleon by 454.1% in the 4th quarter. Bank of Montreal Can now owns 8,500,496 shares of the company’s stock valued at $85,940,000 after purchasing an additional 6,966,416 shares during the period. Finally, Bank of America Corp DE lifted its holdings in shares of Haleon by 116.7% in the second quarter. Bank of America Corp DE now owns 12,384,135 shares of the company’s stock valued at $128,423,000 after purchasing an additional 6,669,923 shares in the last quarter. 6.67% of the stock is currently owned by institutional investors and hedge funds.

Haleon Stock Performance

HLN opened at $9.80 on Tuesday. The business’s 50-day simple moving average is $9.45 and its 200 day simple moving average is $9.85. Haleon PLC Sponsored ADR has a 52-week low of $8.65 and a 52-week high of $11.28. The company has a debt-to-equity ratio of 0.38, a quick ratio of 0.52 and a current ratio of 0.69. The firm has a market capitalization of $43.19 billion, a PE ratio of 25.14, a PEG ratio of 2.26 and a beta of 0.12.

Haleon Cuts Dividend

The business also recently disclosed a dividend, which will be paid on Thursday, September 17th. Stockholders of record on Friday, August 14th will be paid a dividend of $0.0642 per share. The ex-dividend date is Friday, August 14th. This represents a dividend yield of 127.0%. Haleon’s dividend payout ratio is currently 64.10%.

Wall Street Analyst Weigh In

Several research analysts have recently weighed in on the company. Zacks Research cut Haleon from a “hold” rating to a “strong sell” rating in a research report on Tuesday, July 21st. Wall Street Zen raised Haleon from a “hold” rating to a “buy” rating in a research report on Sunday, July 12th. Deutsche Bank Aktiengesellschaft restated a “sell” rating on shares of Haleon in a research note on Thursday, April 30th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Haleon in a research report on Tuesday, June 30th. Finally, Rothschild & Co Redburn cut shares of Haleon from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, June 16th. Two research analysts have rated the stock with a Strong Buy rating, three have given a Buy rating, three have assigned a Hold rating and two have issued a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy”.

Read Our Latest Report on Haleon

Haleon Company Profile

(Free Report)

Haleon plc (NYSE:HLN) is a global consumer healthcare company formed through the separation of a large pharmaceutical group’s consumer health business in 2022. Headquartered in the United Kingdom, Haleon develops, manufactures and markets a broad portfolio of over‑the‑counter medicines, oral health products, vitamins, minerals and supplements, and other consumer health goods designed for daily self‑care and symptom relief.

The company’s product mix spans categories such as oral care (toothpastes and sensitivity treatments), pain relief and analgesics, respiratory remedies, digestive health products, topical treatments and nutritional supplements.